XXXX 150 mg at night in the prevention of @entity2275 .

@entity1 @entity1066 @entity5616 @entity2275
After healing of a @entity2275 , 53 @entity1 were randomly allocated to either 12 months maintenance treatment with @entity5616 150 mg at night or an identical placebo. Fifty @entity1 completed the trial. The @entity1 were interviewed every third month. If symptoms indicated a relapse, endoscopy was done; and if an @entity1066 was found the maintenance trial was terminated. All remaining @entity1 were endoscoped after one year. The accumulated relapse rate in the @entity5616 group (36%) was significantly lower (p less than 0.01) than in the placebo group (76%), as also was the antacid consumption (p less than 0.01). Four of the six @entity1066 found at the final one year endoscopy were asymptomatic. In all but two of the 26 @entity1 with relapse of symptoms an @entity1066 was found at endoscopy. The @entity1 that suffered a recurrence had significantly (p less than 0.05) higher maximal acid output than those without @entity1066 recurrence. The time needed for healing of the relapse @entity1066 (four or eight weeks) corresponded to that needed for healing of the preinclusion @entity1066 . It is concluded that @entity5616 150 mg at night significantly reduces the @entity2275 recurrence rate, and that relapsing @entity1066 are similar to the initial ones in healing response.
